APA

Matulonis U. A., Sharma S., Ghamande S., Gordon M. S., Del Prete S. A., Ray-Coquard I., Kutarska E., Liu H., Fingert H., Zhou X., Danaee H. & Schilder R. J. (20130206). Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. : Gynecologic oncology.

Chicago

Matulonis Ursula A, Sharma Sudarshan, Ghamande Sharad, Gordon Michael S, Del Prete Salvatore A, Ray-Coquard Isabelle, Kutarska Elzbieta, Liu Hua, Fingert Howard, Zhou Xiaofei, Danaee Hadi and Schilder Russell J. 20130206. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. : Gynecologic oncology.

Harvard

Matulonis U. A., Sharma S., Ghamande S., Gordon M. S., Del Prete S. A., Ray-Coquard I., Kutarska E., Liu H., Fingert H., Zhou X., Danaee H. and Schilder R. J. (20130206). Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. : Gynecologic oncology.

MLA

Matulonis Ursula A, Sharma Sudarshan, Ghamande Sharad, Gordon Michael S, Del Prete Salvatore A, Ray-Coquard Isabelle, Kutarska Elzbieta, Liu Hua, Fingert Howard, Zhou Xiaofei, Danaee Hadi and Schilder Russell J. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. : Gynecologic oncology. 20130206.